Abstract
Marinol®, Cesamet®, Sativex ® and Rimonabant are all
commercially-marketed cannabinoids. They treat a variety of conditions from
weight-loss to pain relief. The introduction of cannabinoids into the
pharmaceutical marketplace has begun, and attitudes to the drugs are changing.
This increased acceptance will lead to greater market penetration, and the
importance of the area will be seen with the first cannabinoid reaching
blockbuster status before the end of the decade.
The growth of this class of products has not yet been realised. As a resource
for developing new pharmaceutical products this area will continue to provide
potential for the future, and there will be increased R&D efforts into this
market. But what treatment areas will benefit? What are the products currently
coming through the pipeline? Just how much market potential does this area
offer?
Visiongain' s latest report, Rimonabant: The first of the Cannabinoid
blockbusters, forecasts the cannabinoid market in 2007 to generate $709
million in sales. This has grown 45% from 2006, when it was generating $386
million. The profile of the market will be raised considerably with
Rimonabant, by Sanofi-Aventis, used to treat obesity and set to reach
impressive sales in its first few years. Rimonabant, branded Acomplia and
Zimulti (US), has now been approved for sale in all 25 countries of the
European Union by the European Commission. Make no mistake, major Pharma will
not sit around and watch blockbusters being created without wanting to take
some of the action. Will you be part of the success? Is this an area that your
company is involved in? If not, is it an area you should be involved in? Find
out today.
Buying this report will provide you with the answers you need to make those
business-critical decisions. Designed as a vital business aid, Rimonabant: The
first of the Cannabinoid blockbusters provides the industry' s leading
evaluation of the market. Now in its second edition, the report focuses on the
following aspects of the worldwide cannabinoid market:
- Current Products
- Pipeline Cannabinoid Products
- Company Profiles and Analysis
- Market Activity
- Revenue Forecasts to 2012
- Regulatory Issues of Cannabinoids in each of the eight major markets
- Alternative therapeutic areas
The report provides in-depth market analysis for current and potential
products. The report extensively identifies cannabinoid drugs market potential
by analysing the latest clinical trial research and highlighting new
indications. The study also assesses the challenges faced by potential
companies. Attitudes to cannabinoids are changing - it will experience its
first blockbuster.
Why You Must Buy This Report:
This 190+ paged report features over 25 tables, and over 40 graphs and
figures. The latest news, insights and analysis of the latest developments are
included, with an in depth review of the cannabinoids market. This report is
vital to help gain and develop your understanding of this growing sector of
the pharmaceutical market, and will give your company ' the edge' over your
competitors. You can not afford to be without this latest report from
visiongain.
Five key questions this report answers are:
- What is the market potential for cannabinoids treating various diseases?
- What latest clinical trials/experimental research has been performed to
develop cannabinoids for therapeutic uses?
- What is the global cannabinoid market value today and what is its future
worth?
- When will the cannabinoid market first claim a blockbuster?
- What are the regulatory issues surrounding cannabinoids and medicinal
cannabis use in the eight major markets?
| 
View Cart
